全球mRNA疫苗和治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

全球mRNA疫苗和療法市場預計將從2025年的317.4億美元成長至2034年的1,145億美元，2026年至2034年的複合年成長率（CAGR）為15.32%。隨著基於mRNA的新冠疫苗成功上市，全球mRNA疫苗和療法市場經歷了爆炸性成長。這項技術展現了快速研發能力、高效性和擴充性，徹底改變了疫苗的研發方式。目前，mRNA平台的研究不僅應用於感染疾病，也拓展至癌症免疫療法、罕見遺傳疾病和個人化醫療等領域。

成長要素包括政府的大量撥款、持續的研發投入以及在生物技術領域不斷擴大的夥伴關係。脂質奈米顆粒遞送系統的進步和mRNA穩定性的提高帶來了臨床療效的改善。該平台具有極強的適應性，可以快速進行改造以靶向新出現的病原體，這使其在全球公共衛生工作中具有極高的價值。

隨著製藥公司不斷拓展在自體免疫疾病和代謝失調領域的研發管線，前景一片光明。儲存、分銷和生產流程的持續改進將進一步提升商業性可行性。隨著研究不斷拓展治療適應症範圍，mRNA技術可望徹底革新現代醫學，並確保市場長期永續成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球mRNA疫苗與治療市場：以mRNA類型分類

• 市場分析、洞察與預測
• 核苷修飾的mRNA
• 未修飾的mRNA
• 自擴增mRNA

第5章 全球mRNA疫苗與治療市場：依類型分類

• 市場分析、洞察與預測
• 為了預防
• 治療藥物

第6章 全球mRNA疫苗與治療市場：依應用分類

• 市場分析、洞察與預測
• 感染疾病
• 腫瘤學
• 罕見遺傳疾病
• 其他（呼吸系統疾病等）

第7章 全球mRNA疫苗與治療市場：依最終使用者分類

• 市場分析、洞察與預測
• 醫院和診所
• 生物製藥公司
• 其他

第8章 全球mRNA疫苗與治療市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 中國
  • 日本
  • 韓國
  • 印度
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Moderna
  • BioNTech
  • Pfizer
  • Sanofi
  • CureVac
  • Arcturus Therapeutics
  • GSK
  • CSL/Seqirus
  • Ethris
  • ETheRNA
  • Capstan Therapeutics
  • ReNAgade Therapeutics
  • Tiba Biotech
  • Acuitas Therapeutics
  • Strand Therapeutics
  • Replicate Bioscience
  • Omega Therapeutics
  • Cartesian Therapeutics
  • Sana Biotechnology
  • Abogen

The global mRNA vaccine and therapeutics market size is expected to reach USD 114.50 Billion in 2034 from USD 31.74 Billion in 2025, growing at a CAGR of 15.32% during 2026-2034.The Global mRNA Vaccine and Therapeutics Market witnessed exponential growth following the successful deployment of mRNA-based COVID-19 vaccines. The technology demonstrated rapid development capabilities, high efficacy, and scalability, transforming vaccine research and production. Beyond infectious diseases, mRNA platforms are being explored for cancer immunotherapy, rare genetic disorders, and personalized medicine applications.

Key growth drivers include substantial government funding, ongoing R&D investments, and expanding biotech partnerships. Advances in lipid nanoparticle delivery systems and improved mRNA stability have strengthened clinical outcomes. The platform's adaptability allows quick modification to target emerging pathogens, making it highly valuable in global public health preparedness strategies.

Future prospects are exceptionally strong as pharmaceutical companies expand pipelines for oncology, autoimmune, and metabolic diseases. Continuous improvements in storage, distribution, and manufacturing processes will enhance commercial viability. As research broadens therapeutic indications, mRNA technology is expected to revolutionize modern medicine, ensuring sustained long-term market growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By mRNA Type

Nucleoside-modified mRNA

Unmodified mRNA

Self-amplifying mRNA

By Type

• Prophylactic
• Therapeutic

By Application

• Infectious Diseases
• Oncology
• Rare Genetic Diseases
• Others (Respiratory Diseases, etc)

By End-user

• Hospitals & Clinics
• Biopharmaceutical Companies
• Others

COMPANIES PROFILED

• Moderna, BioNTech, Pfizer, Sanofi, CureVac, Arcturus Therapeutics, GSK, CSL/Seqirus, Ethris, eTheRNA, Capstan Therapeutics, ReNAgade Therapeutics, Tiba Biotech, Acuitas Therapeutics, Strand Therapeutics, Replicate Bioscience, Omega Therapeutics, Cartesian Therapeutics, Sana Biotechnology, Abogen

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MRNA VACCINE AND THERAPEUTICS MARKET: BY MRNA TYPE 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Mrna Type
• 4.2. Nucleoside-modified mRNA Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Unmodified mRNA Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.4. Self-amplifying mRNA Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL MRNA VACCINE AND THERAPEUTICS MARKET: BY TYPE 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Type
• 5.2. Prophylactic Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Therapeutic Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL MRNA VACCINE AND THERAPEUTICS MARKET: BY APPLICATION 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.4. Rare Genetic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.5. Others (Respiratory Diseases, etc) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL MRNA VACCINE AND THERAPEUTICS MARKET: BY END-USER 2022-2034 (USD MN and Million Doses)

• 7.1. Market Analysis, Insights and Forecast End-user
• 7.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.3. Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 8. GLOBAL MRNA VACCINE AND THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN and Million Doses)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.2.1 By Mrna Type
  • 8.2.2 By Type
  • 8.2.3 By Application
  • 8.2.4 By End-user
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.3.1 By Mrna Type
  • 8.3.2 By Type
  • 8.3.3 By Application
  • 8.3.4 By End-user
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Spain
  • 8.3.10 Russia
  • 8.3.11 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.4.1 By Mrna Type
  • 8.4.2 By Type
  • 8.4.3 By Application
  • 8.4.4 By End-user
  • 8.4.5 China
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 India
  • 8.4.9 Australia
  • 8.4.10 South East Asia
  • 8.4.11 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.5.1 By Mrna Type
  • 8.5.2 By Type
  • 8.5.3 By Application
  • 8.5.4 By End-user
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.6.1 By Mrna Type
  • 8.6.2 By Type
  • 8.6.3 By Application
  • 8.6.4 By End-user
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL MRNA VACCINE AND THERAPEUTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Moderna
  • 10.2.2 BioNTech
  • 10.2.3 Pfizer
  • 10.2.4 Sanofi
  • 10.2.5 CureVac
  • 10.2.6 Arcturus Therapeutics
  • 10.2.7 GSK
  • 10.2.8 CSL/Seqirus
  • 10.2.9 Ethris
  • 10.2.10 ETheRNA
  • 10.2.11 Capstan Therapeutics
  • 10.2.12 ReNAgade Therapeutics
  • 10.2.13 Tiba Biotech
  • 10.2.14 Acuitas Therapeutics
  • 10.2.15 Strand Therapeutics
  • 10.2.16 Replicate Bioscience
  • 10.2.17 Omega Therapeutics
  • 10.2.18 Cartesian Therapeutics
  • 10.2.19 Sana Biotechnology
  • 10.2.20 Abogen